Companies · Pharmaceuticals

Third Day Healing Holdings LLC

INDEPENDENCE · Pharmaceuticals

Diligence memoA one-page analyst read on Third Day Healing Holdings LLC — recommendation, valuation, rhythm, risks.
$995K
Total raised · real
1
Rounds
Latest step-up
Top 83%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Mon Nov 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Third Day Healing Holdings LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.48× the median modeled value of Pre-Seed Pharmaceuticals companies in 2010–2012 (71 peers) — value vs value, same stage and era.
Dormant
  • Last raise 15.7 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Third Day Healing Holdings LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
15.7 yr record
Peak capital year was 2010 with $995K across 1 filings.
Market position
ahead of 18% of Pharmaceuticals peers
Capital scale is ahead of 18% of Pharmaceuticals peers; modeled value is above 42% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2010: $995K across 1 filings.
  • Largest single filing was $995K on 2010-11-01.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Third Day Healing Holdings LLC is one of 1610 Pharmaceuticals companies tracked from INDEPENDENCE. By capital raised it ranks in the long tail (ahead of 18% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2010-11-01 Raised $995K (real) Modeled valuation $47M (est)$995K$47MPre-Seed2010

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$995K · 2010

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$47.1M
Base estimate est.
$557K
Conservative case
$533.6M
Upside case
$5.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
15.7 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
15.7 yr
On record since
2010
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$995K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 2.4× above median
This company$995K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$47.1M
Sector median$76.1M

Raised more than 18% of sector peers (real $). Modeled value above 42% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #3 of 71.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Armgo Pharma Inc · Pre-Seed Raised $1.0M · modeled $47.3M (est)Dermal Life, LLC · Pre-Seed Raised $1.3M · modeled $47.3M (est)Dermamedics Llc · Pre-Seed Raised $2.0M · modeled $45.9M (est)China Yongxin Pharmaceuticals Inc. · Pre-Seed Raised $1.4M · modeled $42.6M (est)Flex Biomedical, Inc. · Pre-Seed Raised $2.4M · modeled $41.7M (est)Spaulding Clinical Research Llc · Pre-Seed Raised $1.7M · modeled $41.2M (est)BioAnalytix LLC · Pre-Seed Raised $858K · modeled $40.6M (est)SteadySleep Rx Co. · Pre-Seed Raised $800K · modeled $37.8M (est)Primrose Therapeutics, Inc. · Pre-Seed Raised $753K · modeled $35.6M (est)Century Labs, Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Sommer Pharmaceuticals-II, LLC · Pre-Seed Raised $750K · modeled $35.5M (est)Third Day Healing Holdings LLC (this company) Raised $995K · modeled $47.1M (est)Third Day Healing Holdings LLC
CompanyStageRaised · realValue · estvs peer med.
Armgo Pharma IncPre-Seed$1.0M$47.3M2.50×
Dermal Life, LLCPre-Seed$1.3M$47.3M2.50×
Third Day Healing Holdings LLC this companyPre-Seed$995K$47.1M2.48×
Dermamedics LlcPre-Seed$2.0M$45.9M2.42×
China Yongxin Pharmaceuticals Inc.Pre-Seed$1.4M$42.6M2.25×
Flex Biomedical, Inc.Pre-Seed$2.4M$41.7M2.20×
Spaulding Clinical Research LlcPre-Seed$1.7M$41.2M2.17×
BioAnalytix LLCPre-Seed$858K$40.6M2.14×
SteadySleep Rx Co.Pre-Seed$800K$37.8M2.00×
Primrose Therapeutics, Inc.Pre-Seed$753K$35.6M1.88×
Century Labs, Inc.Pre-Seed$750K$35.5M1.87×
Sommer Pharmaceuticals-II, LLCPre-Seed$750K$35.5M1.87×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$995K2010-11-01$5.5M$47.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$995K2010-11-01
    • First recorded raise — entered as Pre-Seed.
Intelligence
Modeled next raise
$1.6M
Modeled next size est.range $1.0M$2.5M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Daniel R. Storer2010-11
Doug R. Gruen2010-11
Lamont R. Dorsey2010-11
Registry & provenance

Third Day Healing Holdings LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1505063
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Dynamis Pharmaceuticals, Inc.PharmaceuticalsPre-Seed$997K$21.7Msame sector · same stage
Armgo Pharma IncPharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Blake Insomnia Therapeutics, Inc.PharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Elion Oncology, Inc.PharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Enfuego Therapeutics, Inc.PharmaceuticalsPre-Seed$1.0M$27.0Msame sector · same stage
Entopica Therapeutics, Inc.PharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Essentia Pharma Florida, LlcPharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Essentia Pharma Socal, LlcPharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Frequently asked
How much funding has Third Day Healing Holdings LLC raised?
Third Day Healing Holdings LLC has raised approximately $995K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Third Day Healing Holdings LLC's estimated valuation?
Provath's modeled valuation for Third Day Healing Holdings LLC is approximately $47.1M (modeled range $557K–$533.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Third Day Healing Holdings LLC at?
Third Day Healing Holdings LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Mon Nov 01.
What does Third Day Healing Holdings LLC do and where is it based?
Third Day Healing Holdings LLC operates in the Pharmaceuticals sector, based in INDEPENDENCE.
Explore related

See where Third Day Healing Holdings LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Third Day Healing Holdings LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.